MAR 27·Simply Wall StreetMed
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
LENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year's revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.